Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16843333 | 0.84 | GPR3 (0.33) | — | |
| SCHEMBL12424582 | 0.82 | TSHR (0.62) | TSHRALOX15ALOX12CYP1A2CYP2C9 | |
| SCHEMBL10273089 | 0.76 | PTGS1 (0.34) | — | |
| SCHEMBL23480218 | 0.76 | CYP3A4 (0.36) | ALOX15CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL24910672 | 0.70 | TSHR (0.46) | TSHRCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20275984 | 0.69 | TSHR (0.42) | TSHR | |
| SCHEMBL7519328 | 0.67 | TSHR (1.00) | TSHRALOX15ALOX12CYP1A2CYP2C9 | |
| SCHEMBL22792869 | 0.66 | — | — | |
| SCHEMBL22792435 | 0.66 | — | — | |
| SCHEMBL20690300 | 0.66 | LMNA (0.41) | ALOX15CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019280-A1 | SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019280-A1 | SUBSTITUTED ISOINDOLONYL 2,2'-BIPYRIMIDINYL COMPOUNDS, ANALOGUES THEREOF, AND METHODS USING SAME | HAVCR2, CDV3, HCCS | TSHR 4408/4885ALOX15 4317/4885ALOX12 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.